The University of Alberta researcher refused to be interviewed by the Globe and Mail for this story. Additionally, no mention was made of the medical doctor in Toronto who says that he will sell DCA to his patients.

"TheDCAsite.com – that was established by Jim Tassano, a California man who owns a pest-control company. Mr. Tassano wanted to help a favourite ballroom-dancing instructor, who was dying of cancer. It has become an online community, its members united by the hope that DCA will save their lives or someone they love."

"Mr. Tassano has started a second website, BuyDCA.com, where he sells the drugs that he and a chemist friend synthesize themselves, which he says is a simple process."

"Helping cancer patients treat themselves with DCA clearly wasn't what Dr. Michelakis had in mind when he filed the patent, or when he published his results in January in the medical journal Cancer Cell."

Catastrophic risks

What could go wrong?

"Dr. Michelakis and his colleagues have warned that DCA ordered over the Internet may contain dangerous impurities. It is often sold in a highly acidic form that could cause “catastrophic” complications, they explain on the university's own DCA website, www.depmed.ualberta.ca/dca."

"It might interact with other anti-cancer drugs, he has said, and may cause severe nerve damage. People might lose their ability to walk, or speak."

The Canadian Cancer Society is urging people not to take it.

Medicor Cancer Centres Opinions

• McGUINTY USHERS IN MORE U.S.-STYLE HEALTH CARE - NDP critic - May 10, 2006 - 9:00am

  NDP Leader Howard Hampton is raising a red flag about Dalton McGuinty ushering in more U.S.-style health care in the province of Ontario.

  Today, the Medicor Cancer private, fee-for-service clinic is opening in Toronto. Patients have to pay $2,500 to sign up for the health care service, and pay $1,200 a month in ongoing membership fees.

• Discussion in Ontario Legislature on Medicor's opening - May 2006
  (Search text for Medicor)

  Mr. Hampton: The McGuinty government says it stands for medicare. We're asking the McGuinty government to finally take some steps to prevent two-tier health care, something you are so obviously reluctant to do.

  Medicor says, "We also explore options for treatments -- not routinely available to you -- and will coordinate such care if you wish." In other words, those who can pay extra will get preferential access to medical services. Paying your way to the front of the line contradicts the Canada Health Act. Paying for intake services and medical records and turning away patients who can't or won't pay block fees are also illegal under Ontario law and Canadian law. The question is, is the McGuinty government simply going to lecture people or are you actually going to do something to prevent two-tier health care in Ontario?

Clinical Trial Applications in Canada

In order for any health practitioner to use any new medical treatment that involves chemical products or pharmaceutical they must apply for a CTA - Clinical Trial Application. Anyone in medicine knows that, and anyone who refuses to comply with this should not be practicing medicine in this country.

Any medical doctor who has not applied for, or who is not qualified to make an application to market products like DCA should be stopped by Health Canada from importing any product into this country. Furthermore, any medical doctor who uses DCA on patients at any time should be reported to their respective regulatory bodies in Canada.

• Applying to Health Canada: Clinical Trial Applications (CTA)

  The Food and Drug Regulations provide authority to the Health Products and Food Branch (HPFB) of Health Canada to regulate the sale of drugs for the purposes of use in human clinical trials. Division 5 of the Regulations defines specific Clinical Trial Application (CTA) requirements and prescribes a 30-day default review period for these applications. Amendments to Division 5 were announced in June 2001 and took effect September 1, 2001.

  Sponsors must file applications to conduct clinical trials in Phases I through III of drug development. This includes applications to conduct clinical trials involving marketed products where the proposed use of the product is outside the parameters of the approved Notice of Compliance (NOC) or Drug Identification Number (DIN) application, e.g. one or more of the following is different:

     1. indication(s) and clinical use;
     2. target patient population(s);
     3. route(s) of administration, or
     4. dosage regimen(s).
  

More coverage of DCA

Desperate cancer patients clamour for untested DCA "cure" as Internet drug pedlars hijack Alberta researcher's anti-cancer molecule. Dr Evangelos Michelakis is living every researcher's worst nightmare. The therapy he painstakingly studied, verified and re-verified, has been hijacked and risks harming the very people it was intended to help.

A Canadian researcher from the University of Alberta published a study that used DCA in rats, and this has sparked an underground industry in the unapproved chemical. This article is a review of these developments. Links to other sites and opinions.

One study of a model of cancer in "nude" athymic rats, animals that have no immune system so that human tumor lines can be studied inside an organism, and people are rushing to take this stuff.

Foothill Sierra Pest Control is owned by Jim & Ilene Tassano

Pest Control
Mosquito Control
Weed Control
209-532-7378
11072 Mountain Brow Rd 
Sonora, CA 95370